中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
17期
6-8
,共3页
胡光友%葛香丽%赵宝利%王金磊
鬍光友%葛香麗%趙寶利%王金磊
호광우%갈향려%조보리%왕금뢰
铜绿假单胞菌%头孢哌酮钠/舒巴坦%阿米卡星%哌拉西林/他唑巴坦%环丙沙星%降钙素原
銅綠假單胞菌%頭孢哌酮鈉/舒巴坦%阿米卡星%哌拉西林/他唑巴坦%環丙沙星%降鈣素原
동록가단포균%두포고동납/서파탄%아미잡성%고랍서림/타서파탄%배병사성%강개소원
Pseudomonas aeruginosa%Cefoperazone/Sulbactam%Amikacin%Piperacillin/Tazobac-tam%Ciprofloxacin%PCT
目的:探讨头孢哌酮钠/舒巴坦联合阿米卡星及哌拉西林/他唑巴坦联合环丙沙星治疗ICU多重耐药铜绿假单胞菌肺炎的临床疗效及降钙素原( PCT)对临床抗生素使用的指导意义。方法选取ICU确诊为多重耐药铜绿假单胞菌感染性肺炎患者50例,分为试验组(哌拉西林/他唑巴坦﹢环丙沙星)26例和对照组(头孢哌酮钠/舒巴坦﹢阿米卡星)24例,两组抗生素应用前PCT值基本相同,差异无统计学意义,观察相关临床指标。结果试验组有效率为88.5%,对照组有效率为87.5%,差异无统计学意义( P﹥0.05);两组患者在治疗2、7、14、21 d时的PCT均明显改善,试验组改善更明显( P﹤0.05或P﹤0.01);试验组咳嗽咳痰消失时间、白细胞恢复正常时间明显短于对照组,差异有统计学意义(P﹤0.01或P﹤0.05)。两组治疗后血压、脉搏、体温、呼吸比较差异无统计学意义( P﹥0.05)。结论两种方式治疗ICU多重耐药铜绿假单胞菌肺炎均有效,哌拉西林/他唑巴坦联合环丙沙星的效果更明显,两种方法均值得在临床推广应用。
目的:探討頭孢哌酮鈉/舒巴坦聯閤阿米卡星及哌拉西林/他唑巴坦聯閤環丙沙星治療ICU多重耐藥銅綠假單胞菌肺炎的臨床療效及降鈣素原( PCT)對臨床抗生素使用的指導意義。方法選取ICU確診為多重耐藥銅綠假單胞菌感染性肺炎患者50例,分為試驗組(哌拉西林/他唑巴坦﹢環丙沙星)26例和對照組(頭孢哌酮鈉/舒巴坦﹢阿米卡星)24例,兩組抗生素應用前PCT值基本相同,差異無統計學意義,觀察相關臨床指標。結果試驗組有效率為88.5%,對照組有效率為87.5%,差異無統計學意義( P﹥0.05);兩組患者在治療2、7、14、21 d時的PCT均明顯改善,試驗組改善更明顯( P﹤0.05或P﹤0.01);試驗組咳嗽咳痰消失時間、白細胞恢複正常時間明顯短于對照組,差異有統計學意義(P﹤0.01或P﹤0.05)。兩組治療後血壓、脈搏、體溫、呼吸比較差異無統計學意義( P﹥0.05)。結論兩種方式治療ICU多重耐藥銅綠假單胞菌肺炎均有效,哌拉西林/他唑巴坦聯閤環丙沙星的效果更明顯,兩種方法均值得在臨床推廣應用。
목적:탐토두포고동납/서파탄연합아미잡성급고랍서림/타서파탄연합배병사성치료ICU다중내약동록가단포균폐염적림상료효급강개소원( PCT)대림상항생소사용적지도의의。방법선취ICU학진위다중내약동록가단포균감염성폐염환자50례,분위시험조(고랍서림/타서파탄﹢배병사성)26례화대조조(두포고동납/서파탄﹢아미잡성)24례,량조항생소응용전PCT치기본상동,차이무통계학의의,관찰상관림상지표。결과시험조유효솔위88.5%,대조조유효솔위87.5%,차이무통계학의의( P﹥0.05);량조환자재치료2、7、14、21 d시적PCT균명현개선,시험조개선경명현( P﹤0.05혹P﹤0.01);시험조해수해담소실시간、백세포회복정상시간명현단우대조조,차이유통계학의의(P﹤0.01혹P﹤0.05)。량조치료후혈압、맥박、체온、호흡비교차이무통계학의의( P﹥0.05)。결론량충방식치료ICU다중내약동록가단포균폐염균유효,고랍서림/타서파탄연합배병사성적효과경명현,량충방법균치득재림상추엄응용。
Objective To investigate the clinical effects of cefoperazone/sulbactam combined with amikacin and piperacillin/tazobactam combined with ciprofloxacin on multiple drug resistant pseudo-monas aeruginosa infectious pneumonia( MDRPAIP)and the guiding significance of PCI in clinical usage of antibiotics. Methods Fifty patients with MDRPAIP were chose and divided into experiment group (piperacillin and tazobactam combined with ciprofloxacin,26 cases)and control group(cefoperazone/sulbactam combined with amikacin,24 cases). PCT values of the two groups were basically equal,there was no significant difference. The relevant clinical indicators were observed. Results The effective rate was 88. 5% in experiment group and 87. 5% in control group,there was no significant difference( P﹥0. 05);PCT values in both groups at 2nd,7th,14th and 21th day of treatment improved obviously,and those in experiment group improved more obviousely( P﹤0. 05 ,P﹤0. 05 ,P﹤0. 01 ,P﹤0. 01 );The disappearance time of cough and phlegm and time of white blood cell recover to normal level in experi-ment group was obviously shorter than that in control group( P﹤0. 01 ,P﹤0. 05 ). There was no signifi-cant difference in blood pressure,pulse,temperature and respiratory rate between the two groups( P﹥0. 05). Conclusions Both therapies are effective on MDRPAIP,and the effect of piperacillin/tazobac-tam combined with ciprofloxacin is better. Both therapies are worthy to be popularized and applied in clinics.